Key points are not available for this paper at this time.
Patients with hyperkalemia who received ZS-9, as compared with those who received placebo, had a significant reduction in potassium levels at 48 hours, with normokalemia maintained during 12 days of maintenance therapy. (Funded by ZS Pharma; ClinicalTrials.gov number, NCT01737697.).
Building similarity graph...
Analyzing shared references across papers
Loading...
New England Journal of Medicine
The University of Texas Health Science Center at San Antonio
The Royal Melbourne Hospital
National Foundation for Cancer Research
Add This Paper to Your Research Feed
Any time a new paper drops it will be there.
Packham et al. (Fri,) studied this question.